Shuttle Pharmaceuticals, Inc.
Shuttle Pharmaceuticals is a pioneering company focused on developing innovative therapies to increase cancer cure rates, improve patient outcomes, and enhance the effectiveness of radiation therapy (RT). They leverage proprietary technologies to create breakthrough radiation sensitizers and diagnostic tools, aiming to maximize treatment efficacy while minimizing side effects. Their mission is to launch the next generation of radiation oncology treatments with the goal of curing cancer and improving quality of life for patients worldwide.
Industries
Nr. of Employees
small (1-50)
Shuttle Pharmaceuticals, Inc.
401 Professional Drive, Suite 260, Gaithersburg, MD 20879
Products
Ropidoxuridine (oral halogenated pyrimidine radiation sensitizer)
An orally available halogenated pyrimidine developed as a radiation sensitizer; completed Phase I and advanced toward Phase II clinical evaluation for brain tumors, sarcomas and other cancers.
Selective HDAC inhibitor candidates (preclinical)
A portfolio of non-cytotoxic, isoform-selective HDAC inhibitors (including HDAC6-selective compounds) designed to stimulate anti-tumor immunity and act as radiosensitizers.
Pretreatment prognostic blood test for localized prostate cancer (PC-Rad)
A diagnostic blood test concept intended to predict outcomes following radiation therapy for localized prostate cancer to inform treatment decision-making and follow-up.
PSMA-targeting theranostic ligand (radiolabeled diagnostic/therapeutic)
A prostate-specific membrane antigen (PSMA) ligand developed for diagnostic imaging and potential therapeutic (theranostic) applications; includes development of radiosynthetic methods for radiolabeling.
Ropidoxuridine (oral halogenated pyrimidine radiation sensitizer)
An orally available halogenated pyrimidine developed as a radiation sensitizer; completed Phase I and advanced toward Phase II clinical evaluation for brain tumors, sarcomas and other cancers.
Selective HDAC inhibitor candidates (preclinical)
A portfolio of non-cytotoxic, isoform-selective HDAC inhibitors (including HDAC6-selective compounds) designed to stimulate anti-tumor immunity and act as radiosensitizers.
Pretreatment prognostic blood test for localized prostate cancer (PC-Rad)
A diagnostic blood test concept intended to predict outcomes following radiation therapy for localized prostate cancer to inform treatment decision-making and follow-up.
PSMA-targeting theranostic ligand (radiolabeled diagnostic/therapeutic)
A prostate-specific membrane antigen (PSMA) ligand developed for diagnostic imaging and potential therapeutic (theranostic) applications; includes development of radiosynthetic methods for radiolabeling.
Services
Outsourced CDMO services for API manufacture, process research and optimization, working standards creation, and production of clinical drug product using cGMP kilo-labs.
Cell-based cytotoxicity and colony formation assays using cultivated cancer cell lines to evaluate compound efficacy and radiosensitization.
Coordination of early-stage clinical trial activities, protocol support and clinical data management in collaboration with clinical sites and supporting agencies.
Outsourced CDMO services for API manufacture, process research and optimization, working standards creation, and production of clinical drug product using cGMP kilo-labs.
Cell-based cytotoxicity and colony formation assays using cultivated cancer cell lines to evaluate compound efficacy and radiosensitization.
Coordination of early-stage clinical trial activities, protocol support and clinical data management in collaboration with clinical sites and supporting agencies.
Expertise Areas
- Radiation sensitizer drug development
- Epigenetic therapeutics (HDAC-targeted drugs)
- Radiopharmaceuticals and theranostics
- Biomarker discovery and diagnostic test development
Key Technologies
- Selective HDAC6 inhibition
- ATM activation / DNA damage response modulation
- Small-molecule radiosensitizers
- Radiochemistry for PET tracers (18F labeling)
News & Updates
Jun 24, 2025: Shuttle Pharmaceuticals announced the closing of a private placement raising $4.25 million, with plans to use the proceeds for acquisitions, marketing, and general corporate purposes.
Jun 20, 2025: The company announced the pricing of a $4.25 million private placement.
Jun 12, 2025: The reverse stock split will become effective.
In September 2022, Shuttle Pharmaceuticals was awarded patents in the U.S. and Hong Kong for its radiation sensitizing HDAC inhibitor technology platform, aimed at reducing side effects and improving outcomes for cancer patients treated with radiation therapy.
In November 2020, the company was awarded a patent for its dual function HDAC molecules that combine epigenetic inhibition and DNA repair activation for cancer treatment.
Jun 24, 2025: Shuttle Pharmaceuticals announced the closing of a private placement raising $4.25 million, with plans to use the proceeds for acquisitions, marketing, and general corporate purposes.
Jun 20, 2025: The company announced the pricing of a $4.25 million private placement.
Jun 12, 2025: The reverse stock split will become effective.
In September 2022, Shuttle Pharmaceuticals was awarded patents in the U.S. and Hong Kong for its radiation sensitizing HDAC inhibitor technology platform, aimed at reducing side effects and improving outcomes for cancer patients treated with radiation therapy.
In November 2020, the company was awarded a patent for its dual function HDAC molecules that combine epigenetic inhibition and DNA repair activation for cancer treatment.